A decrease in TNFα was consistently observed over each 6-hour treatment period (A, B, and C), achieving significance at p = 0.0022 when all SCD treatment periods A–C were combined (n = 9) and providing strong evidence that the SCD Rx course reduced the chronic systemic inflammation associated with MetS as presented in this model (Figure 5). Here, TNF is linked to metabolic syndrome.